Cardiol Therapeutics
CRDLInstitutional ownership · Q2 2024
Latest quarter (Q2 2026)
Institutional holders
41
+7 (+20.6%) vs Q1 2024
Reported value
$10.8M
-7.8% vs Q1 2024
Shares held
5.4M
-1.2M shares
Quarter
Q2 2024
Period ended Jun 30, 2024
41 institutional managers reported holding 5,391,505 shares worth $10,833,854 on Form 13F for Q2 2024, against 34 in Q1 2024. Share positions on CUSIP 14161Y200 only; option legs and principal-amount lines are not counted.
Top 25 institutional holders · Q2 2024
| # | Manager | Shares | Value | % of portfolio | Change | Position page |
|---|---|---|---|---|---|---|
| 1 | Tejara Capital Ltd | 1,722,243 | $3.5M | 1.26% | +77.8K | Position |
| 2 | AdvisorShares Investments LLC | 1,466,972 | $2.9M | 0.51% | +165.0K | Position |
| 3 | MMCAP International Inc SPC | 924,125 | $1.9M | 0.26% | -1.6M | Position |
| 4 | Lion Street Advisors LLC | 253,281 | $505.4K | 0.19% | +60.6K | Position |
| 5 | Cambridge Investment Research Advisors Inc | 116,131 | $235.0K | < 0.01% | -12.6K | Position |
| 6 | LAIRD NORTON TRUST COMPANY LLC | 100,000 | $202.0K | 0.03% | — | Position |
| 7 | Knoll Capital Management LLC | 100,000 | $202.0K | 0.14% | New | Position |
| 8 | MGO ONE SEVEN LLC | 100,000 | $202.0K | < 0.01% | — | Position |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP LLP | 66,180 | $133.7K | < 0.01% | +20.5K | Position |
| 10 | UBS ASSET MANAGEMENT AMERICAS INC | 55,000 | $111.1K | < 0.01% | New | Position |
| 11 | BANK OF MONTREAL | 50,112 | $106.2K | < 0.01% | +112 | Position |
| 12 | GEODE CAPITAL MANAGEMENT LLC | 52,435 | $105.9K | < 0.01% | — | Position |
| 13 | Foundations Investment Advisors LLC | 48,000 | $97.0K | < 0.01% | New | Position |
| 14 | Marble Harbor Investment Counsel LLC | 36,900 | $74.5K | < 0.01% | — | Position |
| 15 | ARROWSTREET CAPITAL LIMITED PARTNERSHIP | 29,294 | $58.0K | < 0.01% | New | Position |
| 16 | GROUP ONE TRADING L P | 28,292 | $57.2K | < 0.01% | +24.6K | Position |
| 17 | MORGAN STANLEY | 27,300 | $55.1K | < 0.01% | New | Position |
| 18 | ROYAL BANK OF CANADA | 27,105 | $55.0K | < 0.01% | +10.7K | Position |
| 19 | CITADEL ADVISORS LLC | 26,187 | $52.9K | < 0.01% | -34.2K | Position |
| 20 | ENVESTNET ASSET MANAGEMENT INC | 26,167 | $52.5K | < 0.01% | +787 | Position |
| 21 | The Goldman Sachs Group Inc | 23,500 | $47.5K | < 0.01% | — | Position |
| 22 | Baader Bank Aktiengesellschaft | 29,028 | $34.4K | < 0.01% | New | Position |
| 23 | Private Ocean LLC | 15,151 | $30.6K | < 0.01% | — | Position |
| 24 | Atria Investments Inc | 11,165 | $22.6K | < 0.01% | New | Position |
| 25 | Verition Fund Management LLC | 11,109 | $22.4K | < 0.01% | New | Position |
Values as reported on each manager's Q2 2024 Form 13F. Change is in shares against the manager's prior-quarter filing.
13F holders by quarter
| Quarter | Holders | Shares | Value |
|---|---|---|---|
| Q2 2026 | 52 +5 | 29.5M | $31.3M |
| Q1 2026 | 47 +6 | 27.9M | $37.6M |
| Q4 2025 | 41 -7 | 9.1M | $8.7M |
| Q3 2025 | 48 +10 | 7.3M | $7.8M |
| Q2 2025 | 38 | 6.5M | $8.8M |
| Q1 2025 | 38 -4 | 7.7M | $7.4M |
| Q4 2024 | 42 +1 | 7.5M | $9.6M |
| Q3 2024 | 41 | 5.0M | $9.9M |
| Q2 2024 | 41 +7 | 5.4M | $10.8M |
| Q1 2024 | 34 +4 | 6.6M | $11.7M |
| Q4 2023 | 30 -3 | 6.9M | $6.0M |
| Q3 2023 | 33 +3 | 6.4M | $2.6B |
| Q2 2023 | 30 -5 | 6.7M | $6.0M |
| Q1 2023 | 35 +4 | 7.3M | $3.5M |
| Q4 2022 | 31 +10 | 6.8M | $3.6M |
| Q3 2022 | 21 -3 | 4.8M | $4.9M |
| Q2 2022 | 24 -2 | 5.3M | $7.0M |
| Q1 2022 | 26 -6 | 5.4M | $8.3M |
| Q4 2021 | 32 +13 | 5.8M | $10.7M |
| Q3 2021 | 19 | 1.6M | $6.6M |
Q3 2021–Q2 2026, as reported on Form 13F. Earlier quarters are in the ownership explorer below.
Across other SEC filings
Fund holders · N-PORT
1 fund| Fund | Value | % of fund | As of |
|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | $36.5K | < 0.01% | Aug 2026 |
1 fund reported holding $36,472 in total on their latest public Form N-PORT reports, the most recent dated August 2026.
Federal lobbying
Spend, trailing 12 months
$40.0K
Through Q2 2023, from quarterly LD-2 reports
Cardiol Therapeutics lobbying profile
5%+ holders · 13D/G
2 filers| Filer | % of class | Filed |
|---|---|---|
| Tejara Capital Ltd 13G | 5.3% | 2026-09-23 |
| MMCAP International Inc SPC 13G | 17.6% | 2026-08-14 |
Latest Schedule 13D or 13G from each filer naming this CUSIP; stakes a filer has reported closed are left out.
Ownership explorer
Loading ownership explorer…
Security Details
| CUSIP | 14161Y200 |
|---|---|
| FIGI | BBG00M0GNQ75 |
| Symbol | CRDL |
| Type | Common stock |
| Class | COM CL A as filed on 13F |
| Exchange | Nasdaq |
| Company | Cardiol Therapeutics |
Identifier History
| Type | Value | From | To |
|---|---|---|---|
| FIGI | BBG00M0GNQ75 | 2026-02-07 | Current |
| CUSIP | 14161Y200 | 2019-09-20 | Current |
Listing History
| Symbol | Exchange | From | To |
|---|---|---|---|
| CRDL | Nasdaq | 2021-08-11 | Current |
| CRTPF | Nasdaq | 2019-09-20 | 2026-07-18 |